Overview: NGS Dystonia Panel Sequencing TestIntroduction: The NGS Dystonia Panel Sequencing Test sequences dystonia-related genes to diagnose dystonia, causing muscle spasms. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected dystonia.
Other Names: Dystonia NGS Assay, Dystonia Gene Panel.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Dystonia sequencing began in the 1990s with movement disorder research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences dystonia-related genes to diagnose dystonia, guides treatment, and evaluates patients with muscle spasms.
Test Parameters: 1. Dystonia Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle spasms, abnormal posture, or dystonia symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle spasms, abnormal posture, tremor, or family history of dystonia. Include current medications, especially botulinum toxin.
Consent: Written consent required, detailing the tests purpose, dystonia implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze dystonia genes (e.g., TOR1A, THAP1). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for dystonia diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm dystonia, guiding botulinum toxin therapy or genetic counseling. Negative results may require clinical evaluation.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EMG, brain MRI, or neurological exam to confirm dystonia diagnosis.
Test Limitations: Not all dystonia cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN Dystonia Guidelines, 2023; Neurology, Albanese A, 2022.
